Market Place
Sourcing Support
Anebulo Pharma Reports Q1 Fiscal Year 2025 Financial Results
13 Nov 2024 //
BUSINESSWIRE
Anebulo Reports Q4 And FY 2024 Results And Recent Updates
25 Sep 2024 //
BUSINESSWIRE
Anebulo Gets NIDA Grant For Cannabis Toxicity IV Treatment Study
22 Jul 2024 //
BUSINESSWIRE
Anebulo Pharma Reports Q3 FY2024 Financials, Updates
15 May 2024 //
BUSINESSWIRE
Anebulo Reports Second Quarter Fiscal Year 2024 Financial Results
13 Feb 2024 //
BUSINESSWIRE
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results
14 Nov 2023 //
BUSINESSWIRE
Anebulo Pharmaceuticals Announces New CEO
06 Oct 2023 //
BUSINESSWIRE
Anebulo Pharma Announces Appointment of Bimal Shah to its Board of Directors
06 Oct 2023 //
BUSINESSWIRE
Anebulo Reports Fourth Quarter and Fiscal Year 2023 Financial Results
20 Sep 2023 //
BUSINESSWIRE
Anebulo to Present at Upcoming Investor and Scientific Conferences
30 Aug 2023 //
BUSINESSWIRE
Anebulo Receives Positive Feedback from FDA to Advance Phase 3 of ANEB-001
21 Aug 2023 //
BUSINESSWIRE
Anebulo Announces Positive Phase 2 Data Demonstrating Potential of ANEB-001
28 Mar 2023 //
PR NEWSWIRE
Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions
08 Mar 2023 //
PR NEWSWIRE
Anebulo Reports Second Quarter Fiscal Year 2023 Financial Results
10 Feb 2023 //
BUSINESSWIRE
Anebulo Announces Completion of Dosing and Data from PII Study of ANEB-001
09 Jan 2023 //
BUSINESSWIRE
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results
10 Nov 2022 //
BUSINESSWIRE
Anebulo Pharma Announces Appointment of Nat Calloway, Ph.D., to BOD
01 Nov 2022 //
BUSINESSWIRE
Anebulo Pharmaceuticals Appoints Nat Calloway to Board of Directors
01 Nov 2022 //
BUSINESSWIRE
Anebulo Announces Data for ANEB-001 from PII Trial for ACI
26 Sep 2022 //
BUSINESSWIRE
Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing
26 Sep 2022 //
BUSINESSWIRE
Anebulo lifts lid on midphase cannabis intoxication therapy data
26 Sep 2022 //
FIERCEBIOTECH
Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022
20 Sep 2022 //
BUSINESSWIRE
Anebulo Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results
09 Sep 2022 //
BUSINESSWIRE
Anebulo to Host Inaugural R&D Day in New York City on Monday, September 26
23 Aug 2022 //
BUSINESSWIRE
Anebulo drug reduces cannabinoid intoxication in phase 2 study
06 Jul 2022 //
FIERCEBIOTECH
Anebulo Pharma to Announce Topline Data for ANEB-001 from angoing PII Trial
23 Jun 2022 //
BUSINESSWIRE
Anebulo Pharma Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
24 May 2022 //
BUSINESSWIRE
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results
11 May 2022 //
BUSINESSWIRE
